TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Optimal Analgesia in Acute Gastroenteritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* acute gastroenteritis~* VAS scale of pain perception at least 4~Exclusion Criteria:~* pregnancy~* allergy to any one of study preparations~* blood pressure less than 85 on admission~* surgical condition (acute abdomen) suspected or diagnosed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dipyrone (Type: ACTIVE_COMPARATOR): None
- Papaverine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Oral Tofacitinib in Adult Subjects With Discoid Lupus Erythematosus (DLE) and Systemic Lupus Erythematosus (SLE)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: EARLY_PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults 18 years to ≤ 65 years of age with clinical diagnosis of DLE (and at least half of patients with a diagnosis of SLE) as determined by the Principal Investigator by medical history and physical exam.~* Able to understand consent procedure~* Able to comply with protocol activities~* Have had a diagnosis of biopsy proven DLE for at least 6 months prior to Visit 1 (Baseline/Day 1).~* At Screening and Visit 1 (Baseline/Day 1), have had DLE covering at least 5% of total body surface area (BSA) or SLE with DLE covering at least 2% of BSA as determined by the hand print method (one palm is equivalent to 1% BSA).~Exclusion Criteria:~* Patients not able to understand consent procedure~* Patients unable to comply with protocol activities~* Other skin conditions at Baseline that would interfere with evaluation of DLE.~* Topical corticosteroid within the past 2 weeks~* Systemic therapy is allowed if on a stable dose and using for at least 3 months -background therapies outlined in Protocol~* Concomitant use of moderate to potent inhibitors and inducers of CYP3A4/5~* Women who are pregnant or wish to become pregnant, or who are lactating. Women of childbearing potential must use effective contraceptive methods in order to participate in tofacitinib clinical studies~* History of infection requiring hospitalization, parenteral antimicrobial therapy within 6 months prior to first dose of study drug or history of infection requiring antimicrobial therapy within 2 weeks prior to first dose of study drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Tofacitinib citrate (Type: EXPERIMENTAL): All participants will take one 5 mg tablet by mouth in the morning and one tablet by mouth in the evening for the 6-month study duration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Tetracaine Combined Spinal Epidural (CSE) Versus Bupivacaine CSE

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* early labor (\>=2cm but =\<6cm cervical dilation)~* at least 12 years of age~* have an assigned ASA physical status 1 or 2~* singleton pregnancy~Exclusion Criteria:~* contraindications to neuraxial anesthesia~* with allergies to drugs used in the study~* have an assigned ASA status 3 or 4~* advanced labor (\> 6cm cervical dilation)~* less than 12 years of age~* Patients with the potential for distorted epidural anatomy, such as Harrington rods or prior back surgery, will also be excluded.

- Gender: FEMALE
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- tetracaine 2mg (Type: ACTIVE_COMPARATOR): None
- Bupivacaine 2 mg (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Physiological Biomarkers of Cancer Treatment Related Fatigue in Women With Breast Cancer.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed early stage breast cancer.~Exclusion Criteria:~* Not specified.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic Study of Clarithromycin in Very Low Birth Weight (VLBW)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* birthweight \< 1500gm or GA \< 32 weeks~* transtracheal aspirate/gastric juice ; ureaplasma/mycoplasma(+)~Exclusion Criteria:~* sepsis, hypotension, shock~* major congenital anomaly

- Gender: ALL
- Minimum Age: None
- Maximum Age: 1 Month
- Healthy Volunteers: f

Study Arms:
- clarithromycin (Type: EXPERIMENTAL): Population PK

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Glaucoma Eye Drop Instillation: Impact of Education

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Established care with the treating ophthalmologist for at least 6 months~* Diagnosis of open-angle glaucoma or ocular hypertension~* The use of one, two or three self-instilled eye drop medications in one or two eyes~* Age 40-85 years~* Fluency in English~* Best corrected visual acuity (BCVA) of 20/50 or better in each eye~Exclusion Criteria:~* Presence of moderate to severe cognitive deficits~* Presence of a clinically significant tremor~* Mini Mental Status Exam score ≤ 20

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Educational intervention (Type: EXPERIMENTAL): The educational intervention arm will contain subjects who will watch a video on proper eye drop instillation technique.
- Attention placebo (Type: PLACEBO_COMPARATOR): The attention control placebo group will receive an educational intervention that mimics the amount of time and attention received by the treatment group. The video chosen is regarding healthy eating tips.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Satisfaction With Placement of Implantable Venous Access Devices in Patients With Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of a solid tumor malignancy~  * No hematological malignancy~* Patient at the Vanderbilt Oncology Clinic~* Has undergone placement of a subcutaneous, single-lumen venous-access device within the past 6 months~  * No patients who have had ≥ 2 venous-access devices placed by ≥ 1 department~PATIENT CHARACTERISTICS:~* Not specified~PRIOR CONCURRENT THERAPY:~* See Disease Characteristics~* Not currently undergoing preparation for or process of stem cell transplantation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Glycemia in Diabetic Elders Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetics diagnosed for at least 6 months~* Patients ages ≥ 65 years and older~* Active patients in the Bay West Endocrinology practice~* Inadequately controlled on oral agents and/or basal insulin with HbA1c between 8.0% and 12%~* Eligible for randomization to either treatment group~* Patients willing to follow either treatment arm including regimen using one or more injectables~* Patients to have an English Reading Level of Grade 6 or above~* Patients residing at home~Exclusion Criteria:~* Unwilling to use a regimen that may contain using one or more injections~* Using short acting insulin prior to the study~* Using GLP-1 in past 10 weeks~* History of hypoglycemia unawareness or episodes needing emergency intervention~* End-stage renal disease~* Dementia~* Blindness~* Terminal illness

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard Treatment (Type: ACTIVE_COMPARATOR): A regimen with traditional drugs only
- Incretin-based Treatment (Type: EXPERIMENTAL): A regimen including incretin-based drugs

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound Guided Insertion of Sheath Before Angiography or Angioplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* All patients scheduled for angiography or angioplasty in whom both radial and femoral access is possible~Exclusion Criteria:~* Abnormal pulse oxymetry test~* If severe lower-extremity calcification is known to exclude femoral access

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Ultrasound arm - Randomized group (Type: EXPERIMENTAL): Ultrasound guided sheath insertion
- Conventional arm - Randomized group (Type: NO_INTERVENTION): Conventional arm during randomized phase
- Historical control group (Type: NO_INTERVENTION): Conventional arm, non-randomization phase

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study to Evaluate Safety & Efficacy of FLX-787-ODT to Treat Fasciculations in Tongue and Appendicular Muscle in Adult Subjects With ALS

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documented diagnosis of ALS diagnosis of less than 5 years.~* Greater than 6 fasciculations per minute noted at least in the tongue by clinical, ultrasound, or EMG evaluation.~* Normal oral cavity exam at screening.~Exclusion Criteria:~* Presence of clinically significant or unstable condition that would result in an increased risk of study participation or difficulty in interpretation of the study results.~* Tremor or other movement disorder that would interfere with recording.~* Presence of major gastrointestinal disorders, such as inflammatory bowel disease, diverticulitis, active peptic ulcer disease, or significant gastroesophageal reflux disease (i.e., not well-controlled on antacids or proton pump inhibitors), or oral or esophageal lesions/ulcers.~* Presence of laryngospasm or significant swallowing problems.~* Inability to tolerate a spicy sensation in the mouth or stomach.~* Actively using illicit drugs or history of chronic substance abuse within the past year prior to screening, including abuse of alcohol.~* Participated in a clinical study (except natural history studies without administration of an investigational product) within 30 days prior to screening.~* Pregnant, breastfeeding, or planning to become pregnant.~* Blood pressure of ≥160 mmHg systolic and/or ≥100 mmHg diastolic.~* Clinically significant abnormalities in laboratory findings (including screening complete electrolyte panel, complete blood count, liver function tests).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- FLX-787-ODT (orally disintegrating tablet) (Type: EXPERIMENTAL): Single dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Assess the Potential for Adrenal Suppression and Systemic Drug Absorption Following Multiple Dosing With DFD-06

Study Design Characteristics:
- Allocation: None
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects and the parent or legal guardian understand the study procedures and agree to participate by giving assent and written informed consent, respectively. Subject's parent or legal guardian must be willing to authorize use and disclosure of protected health information collected for the study.~* Subjects must be at least 6 years and not more than 16.9 years of age, with body weight greater than or equal to 45 pounds at Screening.~* Subjects must present with a clinical diagnosis of stable (at least 3 months) plaque psoriasis.~* Subjects with psoriasis involving ≥10% Body Surface Area (BSA), not including the face, scalp, groin, axillae and other intertriginous areas at the Baseline Visit.~* Subjects must have an Investigator Global Assessment (IGA) grade of at least 3 (moderate) at the Baseline Visit.~Exclusion Criteria:~* Subject has a current diagnosis of unstable forms of psoriasis including guttate, erythrodermic, exfoliative or pustular psoriasis.~* Subject has a history of organ transplant requiring immunosuppression, HIV, or other immunocompromised state.~* Subject has received treatment for any type of cancer within 5 years of the Baseline Visit except skin cancer and cervical cancer (in situ) are allowed if at least 1 year before the Baseline Visit.~* Subject has a history or presence of intracranial hypertension.~* Subject has had prolonged exposure to natural or artificial sources of ultraviolet radiation within 30 days prior to the initiation of treatment or is intending to have such exposure during the study that is thought by the investigator to likely modify the subject's disease

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- DFD-06 Cream (Type: EXPERIMENTAL): This is a single arm, open label study and there will be no reference or control product used in this study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Calibration Study of a Blood Alcohol Level Smart Watch

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: OTHER
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. 21-55 years of age.~2. Can provide proof of age with state or federal picture Identification.~3. Consumes an average of ≥7 standard drinks per week (women) or ≥14 drinks per week (men) over the 28 days prior to consent.~4. Has consumed at least 4 standard drinks on a single day on at least two days in the past 28 days prior to consent.~5. Has a blood alcohol level = 0.000 at time of consent.~6. Is able to understand and provide written informed consent.~7. Body weight ≥ 120 lbs and ≤ 250 pounds~8. Subjects can speak and understand English~Exclusion Criteria:~1. Currently seeking treatment for alcohol problems or purposefully abstaining from alcohol in an attempt to cut back or quit drinking.~2. Clinical Institute Withdrawal Assessment at ≥10.~3. Meets DSM-5 diagnosis of current major depression, bipolar disorder, schizophrenia, bulimia/anorexia, dementia, or a substance use disorder other than alcohol, nicotine, marijuana, or caffeine~4. If female, pregnant or nursing.~5. If female, does not agree to use an accepted form of birth control~6. Has medical or mental condition for which further alcohol exposure at the planned dose range would be contraindicated.~7. Taking medication for which drinking would be contraindicated.~8. Clinically significant abnormal ECG.~9. AST or ALT ≥ 3x the upper limit of normal.~10. Current risk of suicidality.~11. Has taken medications that are used to treat AUD in the past 90 days.~12. Has received alcohol counseling or other non-pharmacologic intervention to treat alcohol use disorder in the past 90 days.~13. Has urine toxicology results positive for cocaine, opioids, amphetamines, buprenorphine, methadone, or methamphetamines.~14. Smokes greater than 5 cigarettes per day.~15. Unable to comfortably abstain from nicotine for a period of 8 hours.~16. Wearing cologne, perfume, aftershave or any other scented oil or alcohol-based beauty product on the day of the Alcohol Lab Visit.~17. Has dietary restrictions that would preclude participating.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: TEA vs. PVB vs. PCA in Liver Resection Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age \>/= 18 years and \</= 80 years~* Scheduled for elective hepatic resection surgery~Exclusion Criteria:~* Preexisting coagulopathy (INR \>1.5)~* Spinal stenosis~* Local infection in area where catheter will be inserted~* Severe cardiovascular disease (NYHA Class III/IV)~* Severe pulmonary disease (FEV1 \<50% of predicted value)~* Allergy or sensitivity to narcotics or local anesthetics~* BMI \>45~* Inability to give informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Thoracic Epidural (Type: ACTIVE_COMPARATOR): None
- Continuous Paravertebral Catheter (Type: ACTIVE_COMPARATOR): None
- Patient-Controlled Analgesia (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Short Course of Amoxicillin for Erysipelas

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females ≥ 18 years of age~* First episode of erysipelas of a lower leg defined as~  * acute well delineate inflammation than had lasted less than 5 days~ * T°≥ 38°5 at least once during the past 5 days or chills.~ * Score ≥3 : oedema, erythema, pain each scored from 0 to 3 : 0= none, 1= moderate, 3= severe~* Written informed consent provided by the patient~* available health insurance~* accept conditions of the trial~Exclusion Criteria:~* Erysipelas for more than 5 days~* Score \< 3~* Septic shock~* Clinical signs of necrotizing cellulitis or fasciitis, bullous lesions related to necrosis, purpuric lesions or superficial cutaneous necrosis.~* Past history of erysipelas of the same lower leg~* Erysipelas not on the lower leg~* Bilateral erysipelas~* Bite occuring during the preceding 7 days.~* Diabetic foot~* patients who have previously received systemic antibiotherapy within the last 5 days (except one or two doses within last 24 hours)~* History of any hypersensitivity or allergic reaction to beta-lactam drugs~* Known renal or Hepatic failure~* Known HIV infection~* Female patients who are pregnant, lactating (breast milk feeding), or who are of child bearing potential and not using an acceptable method of birth control~* Impossibility to stop immunosuppressive treatment, systemic corticosteroids or nonsteroidal anti-inflammatory drugs.~* Severe gastrointestinal disease, dysphagia or any pathology preventing oral administration of treatment.~* Denied to sign written informed consent~* Unable or unwilling to adhere to the study-specified procedures and restrictions~* Evolutive cancer under treatment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1:Short treatment (Type: EXPERIMENTAL): amoxicillin ; 50 mg/kg/24H ; P.O. ; 3 times/day 6 days.
- 2:Usual treatment (Type: ACTIVE_COMPARATOR): amoxicillin 50 mg/kg/24H ; I.V. ; 3 times/day ; up to apyrexia then amoxicillin ; 50 mg/kg/24H ; P.O. ; 3 times/day up to day 14.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues